Overview

Adaptive Therapy for Post-Second-Line Advanced Breast Cancer

Status:
COMPLETED
Trial end date:
2025-05-28
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to explore the efficacy and safety of adaptive therapy in the treatment of post-second-line metastatic breast cancer.
Phase:
PHASE2
Details
Lead Sponsor:
Sun Yat-sen University
Treatments:
Drug Therapy
eribulin
Gemcitabine
Vinorelbine